Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-03 5:17 pm Sale | 2023-07-03 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 7,797,454 9.900% | -779,345 (-9.09%) | Filing History |
| 2023-06-02 5:05 pm Purchase | 2023-05-31 | 13D | Exelixis, Inc. EXEL | Caligan Partners LP | 910,730 0.280% | 60,730 (+7.14%) | Filing History |
| 2023-05-18 5:24 pm Purchase | 2023-05-17 | 13D | Alimera Sciences, Inc. ALIM | Caligan Partners LP | 915,057,915,057 9.990% | 915,057,190,341 (+126264245.63%) | Filing History |
| 2023-03-28 5:00 pm Purchase | 2023-03-24 | 13D | Alimera Sciences, Inc. ALIM | Caligan Partners LP | 724,716 9.990% | 313,189 (+76.10%) | Filing History |
| 2023-03-27 5:20 pm Unchanged | 2023-03-23 | 13D | Exelixis, Inc. EXEL | Caligan Partners LP | 850,000 0.260% | 0 (Unchanged) | Filing History |
| 2023-03-20 5:00 pm Purchase | 2023-03-09 | 13D | Exelixis, Inc. EXEL | Caligan Partners LP | 850,000 0.260% | 850,000 (New Position) | Filing History |
| 2022-12-30 5:10 pm Sale | 2022-12-29 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 8,576,799 10.800% | -2,868,037 (-25.06%) | Filing History |
| 2022-12-09 5:00 pm Sale | 2022-12-09 | 13D | ADMA Biologics, Inc. ADMA | Caligan Partners LP | 10,264,311 4.600% | -628,926 (-5.77%) | Filing History |
| 2022-08-05 11:13 am Purchase | 2022-08-04 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 11,444,836 14.800% | 1,021,648 (+9.80%) | Filing History |
| 2022-06-07 10:31 am Purchase | 2022-06-03 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 10,423,188 13.500% | 938,350 (+9.89%) | Filing History |
| 2022-05-25 5:18 pm Purchase | 2022-05-19 | 13D | Alimera Sciences, Inc. ALIM | Caligan Partners LP | 411,527 5.900% | 411,527 (New Position) | Filing History |
| 2022-05-03 12:40 pm Purchase | 2022-04-29 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 9,484,838 12.300% | 1,104,573 (+13.18%) | Filing History |
| 2022-03-29 5:14 pm Unchanged | 2022-03-29 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 8,380,265 10.900% | 0 (Unchanged) | Filing History |
| 2022-02-04 08:30 am Purchase | 2022-02-03 | 13D | ADMA Biologics, Inc. ADMA | Caligan Partners LP | 10,893,237 5.600% | 10,893,237 (New Position) | Filing History |
| 2021-12-07 5:05 pm Sale | 2021-12-03 | 13D | Liquidia Corporation LQDA | Caligan Partners LP | 7,167,663 13.900% | -1,160,755 (-13.94%) | Filing History |
| 2021-05-10 5:20 pm Purchase | 2021-04-30 | 13D | Standard BioTools Inc. LAB | Caligan Partners LP | 8,380,265 11.200% | 8,380,265 (New Position) | Filing History |
| 2021-04-15 08:00 am Purchase | 2021-04-12 | 13D | Liquidia Corporation LQDA | Caligan Partners LP | 8,328,418 16.100% | 8,328,418 (New Position) | Filing History |